We were delighted to speak to Dr. Erik Duijvelaar (Amsterdam University Medical Center, Amsterdam, the Netherlands) around the cardiac safety findings from the CounterCOVID study, investigating imatinib for the treatment of COVID-19.
The abstract ‘Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial.‘ (Abstract number: P874) was presented at ATS 2022, 13-18 May 2022.
Questions
- What is the rationale for the use of imatinib in the treatment of COVID-19? (0:26)
- Could you tell us a little about the cardiac safety concerns around prolonged use of imatinib? (1:29)
- What were the aims and design of the CounterCOVID study? (2:42)
- What were the findings in terms of cardiac outcomes? (3:19)
- What were the conclusions of the investigators regarding the use of imatinib? (4:42)
Disclosures: Erik Duijvelaar has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
